TG,
Even the "bogeyman" can't refute the facts.
I first tried to bring your attention to this stock when it was at $12. Right now seems to be a pretty good time to accumulate. It may be 3-6 months before it moves, but when it does, it will move with "thunder". Now is the time to accumulate.
"Berkeley, Calif.--(BW HealthWire)--Nov. 3, 1999--BioTime, Inc. (AMEX:BTX - news) announced today that health insurance reimbursements and HMO coverage of surgical procedures will include the cost of Hextend© when used. During the third quarter of 1999, patients undergoing surgery began to receive Hextend as the plasma volume expander of choice. Hextend is a completely sterilized and fully synthetic physiologically balanced blood plasma volume expander. In clinical studies, Hextend has been shown to be safe even when used in large quantities (up to 2-6 liters) during elective high blood loss surgeries.
BioTime, headquartered in Berkeley, California develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, and other applications.
The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to BioTime's ability to obtain foreign regulatory approval to market Hextend; competition from products manufactured and sold or being developed by other companies; the price of and demand for Hextend; the Company's ability to negotiate favorable foreign licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in Hextend; and the availability of reimbursement for the cost of Hextend (and related treatment) from government health administration authorities, private health coverage insurers and other organizations. These and other risk factors are discussed in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission."
Please pay particular attention to the sentence "During the third quarter of 1999, patients undergoing surgery began to receive Hextend as the plasma volume expander of choice."
The "plasma volume expander of choice". What, exactly, does that mean? To me it means that anesthesiologists recognize the superior benefits of Hextend.
Any comments?
Very best regards,
AD |
